Dr. Thomas E. Sepe, MD

Dr. Sepe practices at Bayside Endoscopy Center in Providence, Rhode Island.

Dr. Sepe's NPI, 1508937889, was assigned on November 10, 2006. Dr. Sepe graduated from Icahn School of Medicine at Mount Sinai in 1988. Dr. Sepe holds Rhode Island license 8371.

Dr. Sepe's primary practice is Bayside Endoscopy Center, at 33 Staniford Street 1st Floor, Providence, RI 02905. The practice phone is (401) 274-1810.

Dr. Sepe's primary practice is Bayside Endoscopy Center in Providence, Rhode Island. Dr. Sepe is also affiliated with The Miriam Hospital. The medical group on file is University Gastroenterology. Dmand AI also links Dr. Sepe to 1 more hospital, 3 medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sepe practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Sepe's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Sepe is licensed in Rhode Island.

CMS data shows 893 Medicare services from Dr. Sepe across 10 procedure codes in 2024, for 533 Medicare patients. Medicare paid $87,406 for them.

CMS counts 533 Medicare patients who saw Dr. Sepe in 2024. The largest group is 75 to 84, with 245 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sepe's median patient age at 68, with 49% women.

In 2024, Dr. Sepe wrote 3,249 Medicare Part D claims for 679 patients. 95% of them were for generic drugs. CMS names the drug for 3,158 of them, across 28 drugs with 11 or more claims each, at $447,792 in total drug cost. In 2023, CMS named 2,999 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Sepe for performance year 2024, reported individually. Dr. Sepe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sepe as offering telehealth. CMS counts 91 procedures of colonoscopy by Dr. Sepe, more than 78% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Sepe, published from 2014 to 2023. 2023 was the busiest year, with 2. The most frequent topics are Hepatitis C, Chronic, Drug Therapy, Combination and Genotype. Dr. Sepe has published most often in Cleve Clin J Med. Dr. Sepe's most frequent co-authors are Brian T. Agganis, MD, David Lee, MD and Richard R. Andrews, MD.

Dmand AI links Dr. Sepe to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Non-alcoholic Fatty Liver Disease, Fatty Liver and Cholangitis. Intercept Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Sepe that name 2 trials.

CMS Open Payments shows 1,382 general payments to Dr. Sepe from 43 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 72% of the total. Gilead Sciences, Inc. paid the most, $287,963. It also lists 43 research payments totaling $73,965 from 2017 to 2024, naming 2 clinical trials.

Dr. Sepe graduated from Icahn School of Medicine at Mount Sinai in 1988.